Pancreatic Cancer Treatment Strategies

0
3Кб

Pancreatic cancer (PC) is a recalcitrant and aggressive disease characterized by high incidence and poor prognosis. The mortality rate of PC is rapidly increasing and PC is expected to be the second most common of all malignant tumors by 2030. Currently, surgery and chemotherapy are still the main treatments for pancreatic cancer. However, pancreatic cancer is aggressive and the early symptoms are not obvious, and most patients are in the middle and late stages when diagnosed, and less than 20% of patients are eligible for surgery. For patients who cannot be surgically removed, chemotherapy is the main treatment, but the efficacy of chemotherapy is not satisfactory and fails to improve the life expectancy of patients.

Why do PC remain difficult to treat?

  • PC is usually asymptomatic and aggressive, and most patients are in an advanced or metastatic state at the time of diagnosis.
  • There is a lack of an accurate and inexpensive screening method that is applicable to the general population.
  • Postoperative recurrence rates are high locally (60%) and systemically (90%), and only 15-20% of patients can be surgically removed.
  • Compared to other cancer types, PC has a unique tumor microenvironment (TME) that limits immune cell infiltration and drug delivery, posing a therapeutic challenge for PC.

PC treatment strategies

Over the past three decades, PC has made few breakthroughs in practice compared to other cancers. Therefore, new treatment options for improvement are highly desirable. Currently, new therapeutic options such as next-generation targeted therapies, tumor microenvironment-targeted therapies, and liposomal therapies are in hot development. Here, we give an overview of some treatment strategies.

Conducting cancer research in the modern laboratory.

  • Drugs targeting the DNA damage-repair (DDR) pathway
    Dysfunctional DNA repair mechanisms are necessary to maintain the integrity of cellular DNA and ultimately lead to the accumulation of somatic mutations that increase the risk of cancer. There are a number of inherited deficiency of genes identified, and are linked to the predisposition of developing PC, such as BRCA1/2, ATM, and PALB2. Deficient DDR mechanisms can enhance immune responses in multiple ways, providing a theoretical basis for the combination of DDR-targeted agents and immunotherapy. There is a growing number of anti-tumor drugs that use DDR deficiency, some of which are under investigation, offering increasing therapeutic possibilities for PC patients.
  • Targeting cancer metabolism
    Changes in the way nutrients are metabolized contribute to the development and progression of PC, but the complex relationship between cancer itself and the patient's body is unclear. There are a large number of metabolic alterations in cancer cells, such as alterations in pH balance and related changes in ion transport systems, which could be potential targets for therapy.
  • Targeting tumor microenvironment
    PC has a peculiar tumor microenvironment (TME), which is characterized by complex stroma and high heterogeneity cellular populations. Specifically, TME consists of extracellular matrix, stromal cells, and cancer cells, such as fibroblasts, myofibroblasts, pancreatic stellate cells (PSCs), immune cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). TME acts as a mechanical barrier around tumors, promoting tumor growth and metastatic spread and impeding proper vascularization, limiting immune cell infiltration and drug delivery. Therefore, targeting the tumor microenvironment may be an effective strategy to overcome tumor drug resistance and promote immune infiltration in PC.
  • Immunotherapy
    Currently, immunotherapy is not effective in PC, mainly because immunosuppressive TME acts as a barrier to effector immune cell infiltration. Many studies are still underway, including monoclonal antibodies, cancer vaccines, drugs that target immune system checkpoints, and so on.

Learn more:drugs targeting the DNA DDR pathway

Спонсоры
Поиск
Спонсоры
Категории
Больше
Другое
Molecular Diagnostics Market Overview: Regional Trends and Forecast to 2034
In the realm of medical diagnostics, molecular diagnostics has emerged as a...
От SUBMISSION 2025-01-13 09:48:28 0 2Кб
Technology
Subscription and Billing Management Software Market Business Outlook: Key Growth Factors and Emerging Trends, Forecast to 2033
Subscription and Billing Management Software Market : The Global Subscription and Billing...
От DhirajV 2025-04-15 10:28:22 0 2Кб
Другое
Blog für Spendenanfrage+Spendenbox aufstellen+Spenden Apps+Crowdfunding privat
Eine überzeugende spendenanfrage an firmen zu formulieren, ist ein wichtiger Schritt, um...
От crowdfunding12 2025-04-04 05:30:10 0 1Кб
Health and Wellness
Reaching Out to Sperm and Egg Donors. Weighing the risks and rewards when deciding whether to attempt contact. Reviewed by Ray Parker
KEY POINTS- Reaching out to your own or your child's biological parent can be an exciting,...
От Ikeji 2023-07-07 04:29:26 0 4Кб
News
S.Korean Hanwha Bags Another European Deal! Signs Contract With Romania For K9 & K10 Artillery Systems
10th July, 2024 _ Hanwha Aerospace signed a contract with Romania over the supply of 54...
От Ikeji 2024-07-11 03:41:47 0 2Кб
Спонсоры
google-site-verification: google037b30823fc02426.html